Matt Angel, PhD, on Addressing Unmet Needs in Acute Myeloid Leukemia and Solid Tumors

Video

The chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.

“[T]here are just so few ways of penetrating the tumor microenvironment in solid tumors. Chemotherapy combined with resection [and] radiation, of course, is the standard of care for almost all solid tumors. And for a variety of solid tumors—glioblastoma is a great example—the latest technologies in those areas are usually ineffective.”

Acute myeloid leukemia (AML) remains a particularly devastating cancer, with the onset of severe symptoms often occurring just weeks after diagnosis. Meanwhile, many unmet needs remain for patients with solid tumors as well, with the difficulty of penetrating the solid tumor microenvironment representing a serious challenge for further treatment when first-line therapies are ineffective.

In a November 2022 interview with CGTLive, Matt Angel, PhD, chief executive officer and president, Eterna Therapeutics, discussed the company’s new collaboration with Michael Andreeff, MD, PhD, professor of leukemia, The University of Texas MD Anderson Cancer Center, which will be focused on addressing the unmet needs described above via evaluation of the company’s preclinical gene-edited induced pluripotent stem cell (iPSC)-derived therapeutic candidates for the treatment of AML and solid tumors, and potentially other indications, as well.

In addition to discussing the details of the collaboration, Angel spoke about the company’s broader portfolio. He also discussed the Eterna Therapeutics' decision to use a non-viral, mRNA-based approach to cell engineering, going over the advantages of this method in comparison to other methods.

REFERENCE
Eterna Therapeutics announces research collaboration to develop advanced gene-edited iPS cell therapies. News release. Eterna Therapeutics Inc. November 12, 2022. https://www.globenewswire.com/news-release/2022/11/01/2545499/0/en/Eterna-Therapeutics-Announces-Research-Collaboration-to-Develop-Advanced-Gene-Edited-iPS-Cell-Therapies.html 
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Related Content
© 2024 MJH Life Sciences

All rights reserved.